Citation Impact
Citing Papers
The IASP classification of chronic pain for ICD-11: chronic primary pain
2018 Standout
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
2014 Standout
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
2016 Standout
Do Prognostic Parameters of Remission versus Relapse after Bacillus Calmette–Guérin (BCG) Immunotherapy Exist? Analysis of a Quarter Century of Literature
2003
Optimal Management of the T1G3 Bladder Cancer
2005
Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long‐term analysis of 132 patients
2007
Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high‐grade bladder cancer? A long‐term follow‐up of a randomized study
2007
Lessons learned — resolving the enigma of genetic factors in IBS
2016
The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer
2010
The health economics of bladder cancer
2003
BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer
2002
Irritable bowel syndrome
2016 Standout
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
2013 Standout
Economic aspects of bladder cancer: what are the benefits and costs?
2009
Prognostic Factors in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials
2007
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review
2005
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
2006 Standout
Prevalence of Gastro-Esophageal Reflux-Type Symptoms in Individuals With Irritable Bowel Syndrome in the Community: A Meta-Analysis
2012
EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ
2005
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
Photodynamic therapy and anti-tumour immunity
2006 Standout
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
Epidemiology and Risk Factors of Urothelial Bladder Cancer
2012 Standout
Long‐term follow‐up of noninvasive bladder tumours(stage Ta): recurrence and progression
2000
Early Versus Deferred Cystectomy for Initial High-Risk pT1G3 Urothelial Carcinoma of the Bladder: Do Risk Factors Define Feasibility of Bladder-Sparing Approach?
2007
Preliminary European Results of Local Microwave Hyperthermia and Chemotherapy Treatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma of the Bladder
2004
Intravesical Bacillus Calmette-Guerin Treatment Improves Patient Survival in T1G3 Bladder Tumours
2002
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
2005
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
2012 Standout
Familial Aggregation of Irritable Bowel Syndrome: A Family Case–Control Study
2010
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
2008 Standout
TUR and Adjuvant Intravesical Chemotherapy in T1G3 Bladder Tumors: Recurrence, Progression and Survival in 137 Selected Patients Followed Up to 20 Years
2003
Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature
2012
Functional dyspepsia
2017
HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL
2005
Irritable Bowel Syndrome
2015 Standout
What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases
2019 Standout
Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome
2012
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.
2003
Dyspepsia and irritable bowel syndrome in China: a population‐based endoscopy study of prevalence and impact
2010
Initial Tumor Stage and Grade as a Predictive Factor for Recurrence in Patients With Stage T1 Grade 3 Bladder Cancer
2004
A Retrospective Analysis of 153 Patients Treated With or Without Intravesical Bacillus Calmette-Guerin for Primary Stage T1 Grade 3 Bladder Cancer: Recurrence, Progression and Survival
2003
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
UPPER URINARY TRACT TUMORS AFTER PRIMARY SUPERFICIAL BLADDER TUMORS: PROGNOSTIC FACTORS AND RISK GROUPS
2000
MULTIVARIATE ANALYSIS OF CLINICAL PARAMETERS OF SYNCHRONOUS PRIMARY SUPERFICIAL BLADDER CANCER AND UPPER URINARY TRACT TUMOR
2005
Irritable bowel syndrome is associated with novel inflammatory markers derived from hemogram parameters
2020 Standout
Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma
2003
Irritable bowel syndrome: a gut microbiota-related disorder?
2016
Works of A. Lembo being referenced
Influence of genetics on irritable bowel syndrome, gastro‐oesophageal reflux and dyspepsia: a twin study
2007
Intravesical bacille Calmette-Guérin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up
1999
Intravesical Instillation of Mitomycin-C in 242 Patients with Superficial Bladder Cancer at High Risk of Recurrence: Long-Term Results
1998
Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients
1999
Low Dose Pasteur Bacillus Calmette-Guerin Regimen in Stage T1, Grade 3 Bladder Cancer Therapy
1996
LOW DOSE BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER: LONG-TERM RESULTS
2000